Hopkinson Craig C. sold $464K of ALKS
Hopkinson Craig C. (EVP R&D, Chief Medical Officer) sold 9,000 shares of Alkermes plc. (ALKS) at an average of $51.51 ($51.46–$52.13, $0.46M total) across 2 trades on 2026-07-01 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the same-day execution details (9,000 shares sold at ~$51.46–$52.13) and that it was under a pre-arranged 10b5-1 plan.
Market read
Traders may treat this as routine insider activity with limited fundamental implications, but it can marginally influence sentiment around ALKS.
What to watch
The sale size ($463.6k) is modest relative to a large-cap biotech; without additional context (e.g., option exercises, tax-related sales), the signal is limited.
Background
The article is an SEC Form 4 insider transaction disclosure for Alkermes plc, naming EVP R&D and Chief Medical Officer Craig Hopkinson.
Ticker impact
Alkermes (ALKS) disclosed via Form 4 that EVP R&D/Chief Medical Officer Craig Hopkinson sold 9,000 shares on 2026-07-01 under a 10b5-1 plan.
Low likelihood of a sustained price move; any impact is likely limited to short-term sentiment around the filing date.
The filing specifies an open-market sale and confirms the trades were executed under a pre-arranged Rule 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.
Market effects
No direct sector read-through; this is company-specific insider transaction disclosure.
None indicated.
None indicated.
Counterpoint
Even with a 10b5-1 plan, repeated insider selling can still coincide with internal caution; traders may watch for follow-on disclosures or changes in selling patterns.
Key entities
- issuerAlkermes plc
Subject of the Form 4 insider transaction disclosure (ALKS).
- insiderCraig C. Hopkinson
EVP R&D and Chief Medical Officer who sold shares under a 10b5-1 plan.
